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The neuroleptic malignant syndrome (NMS) occurs as a hypersensitivity response in certain patients exposed to neuroleptics. It is a relatively rare, but potentially lethal complication, the incidence of which may have been underestimated. Recent interest in NMS has arisen due to the recognition that specific therapy may now be available. This review summarises the clinical features and discusses recent ideas regarding aetiology and treatment.
Neuroleptics were first used in the treatment of psychiatric disorders in the 1950s and their side effects are generally well recognised (Marsden & Jenner, 1980) . Preston (1959) first described the clinical features of an uncommon hypersensitivity reaction to neuroleptics, which subsequently became known as the neuroleptic malignant syn drome (NMS). This term was first introduced into the English literature by Delay & Deniker (1968) , although a similar syndrome, the syndrome â€oe¿ Neurovegatif malinâ€•was at that time well recog nised in France (Delay eta!, 1969) . Sporadic reports have since occurred from other countries (Itoh et a!, 1977; Singh, 1981) and considerable interest in this disorder arose in America following a major review by Caroff in 1980. Reference to NMS in the UK literature is sparse, although two recent editorials (Lancet, 1984; Szabadi, 1984) (Cope & Gregg, 1983) .Clough (1983)subsequently describeda further case, and suggestedthat the dis order was more common than has generally been accepted. Until recently, no specific treatment was available for NMS, which carries a mortality of about 20%.
Incidence
The incidence of NMS is unknown, since no major series has been described, but in a review of 60 cases in the world literature, Caroff (1980) quoted an age range of 3 to 61, with 80Â°lo under the age of 40, and a male to female ratio of 2:1. He regarded this condi tion as a â€oe¿ neglected clinical problem of major pro portionsâ€•,which â€oe¿ may be unrecognised and under diagnosed.â€ •Delay & Deniker (1968) estimated the incidence to be 0.5 to 1% in patients taking neuro leptics. On the other hand, Baastrup et a! (1976) described 425 patients taking a combination of halopendol and lithium, none of whom developed NMS. Singh (1981) treated 1,500 patients over a six year period with neuroleptics, and observed three casesâ€"an incidence of 0.2Â°lo, while Itoh et al(1977) collected the largest series yet reported, 14 cases in five years. Of these patients, the majority developed symptoms shortly after the initiation or alteration of neuroleptic therapy.
Aetiology
NMS appears to be an idiosyncratic reaction to a therapeutic dose of the neuroleptic, and it has been suggested that its appearance relates to a critical level of the drug in a predisposed patient (Caroff, 1980 features usually progress over a period of 24â€"72 hours after onset. They tend to subside 5â€"10days later, when related to oral preparations, and 10â€"21 days after long-acting phenothiazines (Smego & Durack, 1982) . Allan & White (1972) reported that the reduction in clinical signs coincided with a fall in the urinary concentration of fluphenazine break down products. Re-exposure of the patient to the same neuroleptic, following recovery, may or may not result in recurrence of symptoms, suggesting that variables other than the neuroleptic drug alone may be involved (Smego & Durack, 1982) .
NMS has been reported following the use of a large number of different neuroleptics, used alone or in combination with other agents such as lithium and tricyclic antidepressants (Smego & Durack, 1982) . It has also been described after dopamine depleting drugs, such as tetrabenazine and alpha methyltyrosine (Burke et a!, 1981) . It is not specific to patients treated for psychiatric disorders since it has also occurred in Huntington's disease (Burke et a!, 1981) , pre-induction anaesthesia (Haberman, 1978) , hypnotic withdrawal (Greenblatt et a!, 1978) and in a non-psychotic child (Shields & Bray, 1976) . NMS may also occur following withdrawal of drugs such as levodopa and amantadine, whose effects enhance central dopaminergic neurotransmission (Toru et al, 1977; Simpson & Davis, 1984) .
Caroff (1980) suggested that organic brain disease might be a predisposing factor, since 11 out of 60 patients with NMS had either brain damage or a history of alcohol or drug abuse prior to neuroleptic exposure. The potential of a phenothiazine for pro ducing the syndrome appears to parallel the anti dopaminergic potency of the drug administered (Itoh et al, 1977) .
Clinical features
The cardinal clinical features of NMS are the development of hyperthermia, muscle rigidity, and autonomic instability in a patient exposed to neuro leptics; this can best be described by reference to a patient seen recently. A 26-year-old female pre sented with a four-day history of acute psychiatric disturbance, which developed on a background of normal personality, except for a short period of panic attacks three years previously. In the four days prior to her admission, she had initially become withdrawn, then restless and agitated, did not sleep, developed visual and auditory hallucinations, and became suspicious of her relatives. On admission to the psychiatric unit, she was noted to be dis orientated in space and time, had no insight into her condition, and was uncooperative, with incoherent speech. There were no focal neurological signs and general examination was normal.Therewas no evidence ofsystemic disorder oralcoholic abuseto indicate a possible organic toxic confusional state, and the initial diagnosis was of a functional psychosis related toacute emotional stress. Shewas treated withlorazepam, 2.5mgs,tds; temazepam, 20 mgs,nocte, andchlorpromazine, 100mgs intra muscularly forthree days. Following thethird dose ofchlorpromazine, shedeveloped a temperature of 38Â°C and became drowsy. Tone in the limbs was normal at this stage. Investigations showed an ESR of 33 mm inthefirst hour,normalCF brain scan and CSF examination, but an abnormal EEG, with a diffuse mixture of fast and slowrhythms. The chlorpromazine was discontinued. Over the succeeding four days, the pyrexia increased to 39.5Â°Cand she developed sweating, tachycardia (120 per minute), and tachypnoea. She became more unresponsive, requiring nasogastric-feeding and bladder catheterisation. Choreiform movements of the limbs and face became prominent, but there were no long-tract neurological signs. Catatonia due to a psychosis was considered and she was given two ECTs; following the second treatment, she was able to understand commands and to walk with help. Smego & Durack (1982) have suggested that alertness and cooperation are often retained in the early stages of NMS. This patient at no stage developed the pulmonary congestion which was originally described as a cardinal feature of NMS (Delay & Deniker, 1968) , but it now seems likely that this is a secondary complication.
The diagnosis of NMS is made on clinical grounds, since laboratory investigations show secondary or non-specific changes only. Thus, a neutrophil leucocytosis occurs without evidence of infection, and liver transaminases may be elevated.
A rise in creatine phosphokinase (CPK) and serum potassium are indices of skeletal muscle necrosis.
The EEG may show non-specific slow wave abnor malities, but CT brain scans and CSF examination are invariably negative. Postmortem studies (Morris et al, 1980; Cope & Gregg, 1983) (Ayd, 1956; Zelman & Guillan, 1970) . Muscle rigidity is not usually a prominent feature of this condition, however. Stauder's lethal catatonia (Stauder, 1934; Billing & Freeman, 1943) wasdescribed manyyears before neuroleptics were introduced, and is clinically indis tinguishable from NMS, though the patho physiological relationship between these two con ditions is unclear. It is usually preceded by a prodromal phase lasting 1â€"2weeks, following which the patient displays features of anxiety and restlessness; sudden clinical deterioration then occurs, the conscious level decreases, body tempera ture rises dramatically, and vasomotor collapse ensues. Postmortem studies have revealed small discrete haemorrhages in the hypothalamus and pituitary (Billing & Freeman, 1943) . Malignant hyperpyrexia is a hypersensitivity reaction which occurs in genetically predisposed individuals who are exposed to certain anaesthetics (Gronert, 1980) . The underlying abnormality lies within skeletal muscle, and the condition is characterised by the development of intense muscle spasm and hyperpyrexia, within minutes of anaesthetic induction. There is often a positive family history, and it carries a 70% mortality. Although an association between malignant hyperpyrexia and NMS has not been definitively established, Caroff et a! (1983) demonstrated that striated muscle from a patient who had recovered from NMS showed a response diagnostic of the susceptibility to malignant hyperpyrexia, when exposed to halothane in vitro.
Conversely, Denborough et a! (1984) described the occurrence of NMS following treatment with fluphenazine in a patient with the muscle disorder which predisposes to malignant hyperpyrexia. In a clinical context, however, diagnostic confusion between these two disorders should not occur, since the pattern of clinical presentation of each is distinct.
Pathophysiology
It is widely recognised that phenothiazines may reduce body temperature and that hypothermia may be a complication of their use (Exton Smith, 1972) .
They have been used to treat life-threatening hyper pyrexia due to heat stroke (Hoagland & Bishop, 1961 ), yet the sites and mechanisms of their thermo regulating action in man are largely unknown.
Animal experiments have demonstrated consider able variation in thermo-regulatory response to neuroleptics, depending upon the species studied and the site of drug administration. Thus, both rats (Hofmann & Zarrow, 1958) and monkeys (Chai et a!, 1976) show a precipitous fall in body temperature when chlorpromazine is injected subcutaneously, whereas, when injected directly into the rostral hypothalamus or third ventricle of the rat, it pro duces prolonged hyperthermia (Rewerski & Jon, 1968) . Further animal studies have demonstrated variation in thenmo-regulatory response to pheno thiazines, depending upon the age, sex, and social conditions of the animals (Barbelby & Loepfe Hinkaanen, 1979) .
In man, it has been suggested that certain corn binations of factors become operative in rendering an individual susceptible to NMS at any given time (Caroff, 1980); e.g.Itoheta!(1977) foundthat exhaustion and dehydration were commonly present at the initiation of phenothiazine therapy. Debate has arisen as to whether the muscle rigidity and hyperpyrexia originate from an effect of the central action of drugs, or are due to a peripheral effect within skeletal muscle. In malignant hyperpyrexia, where the primary disorder lies within the muscle tissue, the extreme spasm of the muscles is sufficient to generate a dramatic rise in body temperature, and a similar mechanism has been considered for NMS. The evidence for this belief was provided by in vitro studies on muscle biopsy specimens (Caroff et a!, 1983; Denborough et a!, 1984) . Further evidence comes from the effect of dantrolene, a drug acting peripherally on skeletal muscle, which produced a rapid relaxation in muscle tone in a patient with NMS and a coincidental fall in body temperature from 42Â°C to normal (Goulon eta!, 1983 ). Granato et a! (1983 found that dantrolene normalised body temperature within 12 hours of administration and that the elevated CPK fell within 48 hours, but their patient remained rigid, tremulous, and stuporose until bromocriptine, a central acting dopamine receptor agonist, was given five days later. Morris et a! (1980) , in contrast, favoured a central mechanism for both the pyrexia and rigidity since curareâ€"a neuromuscular blockerâ€"produced complete flaccidity in a case of NMS, an effect not seen in malignant hyperpyrexia. The pyrexia improved slightly following muscle relaxation, but did not normalise for a further 19 days. In the patient described above, pyrexia was an early feature, in association with stupor and autonomic signs. Muscle rigidity only developed at a later stage, suggesting that at least in the early stages of this condition, the hyperpyrexia has a central origin, and probably arises from an effect upon the hypothalamic thermo-regulatory centres.
Treatment
Until recently, the management of established NMS has relied upon supportive therapy for the cardio respiratory complications. It is clearly imperative that neuroleptics are stopped immediately the con dition is suspected; strenuous attempts must be made to reduce the body temperature, respiratory support may be required via artificial ventilation, and secondary infections will require antibiotics. Renal dialysis has been described in a patient who developed acute renal failure secondary to wide spread rhabdomyolysis (Samii eta!, 1976) , but is not effective in removing circulating neuroleptics, which are protein and lipid-bound (Caroff, 1980) . More specific measures aimed at reducing muscle tonehaveincluded anticholinergics, butthese drugs are generally regarded as ineffective (Itoh et a!, 1977) . ECT also was ineffective in two patients, one of whom had a cardiac arrest during the procedure (Regestein et a!, 1977) .
There are recent reports of two separate lines of treatment, which may be complementary. Since blockade of hypothalamic dopamine receptors by neuroleptics is the probable initiating mechanism, the effects of drugs which facilitate central dopaminergic mechanisms have been studied. Limited success was achieved with amantadine (McCarron et a!, 1982; Gelenberg & Mandel, 1977) but more recently bromocriptine, in a daily dose of 60 mg, was shown effectively to reduce muscle tone andtoimprove conscious level (Granato eta!, 1983; Mueller et a!, 1983) . The complementary use of dantrolene (10 mg/kg) to reduce muscle tone by a peripheral effect has been demonstrated on a number of occasions (Delacour et a!, 1981; Boles et a!, 1982; Coons et a!, 1982; Goekopp & Carbaat, 1982; Goulon et a!, 1983; Granato et a!, 1983; May et a!, 1983) and at present, the best drug treatment for NMS appears to be a combination of bromo criptine and dantrolene.
Conclusions
Much remains to be learned about the conditions which lead to the development of NMS, which, although a relatively rare complication of neuro leptic therapy, hasperhaps beenunderestimated in incidence. There is a need for caution when using potent neuroleptics, and the combination of a greater awareness of this condition with the development of more specific forms of treatment may lead to future improvements in the prognosis. Delay & Deniker (1968) 
